ERBB2 and breast carcinoma: In the study, the distribution of breast cancer molecular subtypes was as follows: 58 cases (18.5%) belonged to the Luminal A subtype, 65 cases (20.8%) were identified as the HER2-enriched subtype, 63 cases (20.1%) were categorized as the Luminal B HER2-negative subtype, another 63 cases (20.1%) fell into the Luminal B HER2-positive subtype, and finally, 64 cases (20.4%) were designated as the Triple-negative subtype.